Press release -
Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity
Rituximab, a chimeric monoclonal antibody against CD20, was one of the first therapeutic antibodies within the oncology field to receive approval by the FDA in 1997. Ever since biosimilar and innovative biologicals with similar mechanism of action have been developed and marketed.
Antibody-dependent cell-medicated cytotoxicity (ADCC) can now, using our new iLite® ADCC Activity Assays, be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be the first to be launched, followed by HER2, EGFR and membrane bound TNF-alpha Target cells.
"Antibody therapy has been proven to be highly powerful for cancer treatment and an important mechanism is the ability of antibody drugs to kill targeted tumour cells by Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC).” comments CEO Else Beth Trautner. “During the last 6 months we have launched six new and unique iLite reporter cell lines. The addition of the iLite ADCC product line complements our existing assay solutions, and cements Euro Diagnostica's position as a supplier of products and services for the pharma industry”, continues Mrs. Trautner.
Product details:
The iLite® anti-CD20 ADCC Activity Set contains 3 different genetically modified cell lines; a reporter Effector cell, a positive Target cell and a negative Target cell. All three products can be supplied individually or in combination as in the iLite anti-CD20 ADCC Activity Set. This set of cells enables measurements of an anti-CD20 drug’s ability to induce ADCC, allowing the results to be read within 5 hours, and does not require any cell culturing. In addition, the Effector cells, which can be used with any Target cell, include a normalization readout which can adjust for differences in cell counts.
As all iLite cell lines, the ADCC products are provided as Assay Ready Cells, and can also be set up in compliance with GLP and GCP at our bioanalytical service laboratory. “The launch of the first products in the iLite ADCC product line, with its advantageous features, enables us to assist clients in accelerating their drug discovery and development programs” adds Trine Österbye, VP BioPharma Solutions.
Related links
Topics
- Diseases
Categories
- ilite cell-based assays
- corporate
- product
- expert partnership
About Euro Diagnostica AB
Euro Diagnostica facilitates the development of safe and efficient drugs and optimal treatment of patients by providing cutting edge assays. By offering versatile assay solutions to pharma, biotech and CRO customers Euro Diagnostica is an optimal partner in drug development from the exploratory phase to and beyond clinical trials. We also provide clinical labs and physicians with cutting-edge tools to aid in diagnosis, prognosis, monitoring and treatment of inflammatory and related diseases.
The iLite® technology, is a proprietary cell-based reporter gene system, utilizing the latest state of the art molecular techniques to generate highly specific, sensitive and unique products. Through its specificity for the drug target and a rapid test format, iLite cell lines facilitate the development and manufacturing of new drugs. iLite is already used by the top ten pharma companies in the world. Read more about iLite.
